Will a “multivitamin” a day keep the “MASLD doctor” away?

Abstract

This commentary discusses the results of a study that assessed the relationship between homocysteine metabolism and histological severity of metabolic dysfunction-associated steatotic liver disease (MASLD), and applied a mathematical model to examine how replacement with different cofactors (pyridoxine, cobalamin, betaine, and folate) may affect homocysteine levels in patients with MASLD. It highlights the clinical implications of the study and examines the pathophysiological support behind the detected associations. It also discusses its limitations, emphasizing the need for further longitudinal and interventional studies to confirm whether modulating homocysteine levels could be a viable therapeutic strategy for MASLD.

Keywords

Metabolic dysfunction-associated steatotic liver disease / steatohepatitis / cofactors / one-carbon metabolism / MASH

References

[1] Suzuki A,Reed MC.Lower hepatic CBS and PEMT expression in advanced NAFLD: inferencing strategies to lower homocysteine with a mathematical model.Metab Target Organ Damage2024;4:21

[2] Finkelstein JD.The metabolism of homocysteine: pathways and regulation.Eur J Pediatr1998;157:S40-4

[3] Blom HJ.Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects.J Inherit Metab Dis2011;34:75-81 PMCID:PMC3026708

[4] da Silva RP, Eudy BJ, Deminice R. One-carbon metabolism in fatty liver disease and fibrosis: one-carbon to rule them all.J Nutr2020;150:994-1003

[5] Tripathi M,Zhou J.Vitamin B₁₂ and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.J Hepatol2022;77:1246-55

[6] Yuan S,Dan L.Homocysteine, folate, and nonalcoholic fatty liver disease: a systematic review with meta-analysis and Mendelian randomization investigation.Am J Clin Nutr2022;116:1595-609

[7] Sarna LK,O K.The CBS/CSE system: a potential therapeutic target in NAFLD?.Can J Physiol Pharmacol2015;93:1-11

[8] Kotani K,Miura K.Paraoxonase 1 and non-alcoholic fatty liver disease: a meta-analysis.Molecules2021;26:2323 PMCID:PMC8072946

[9] Subudhi S,Dichtel LE.Distinct hepatic gene-expression patterns of NAFLD in patients with obesity.Hepatol Commun2022;6:77-89 PMCID:PMC8710788

[10] Balsa E,Bennett CF.Defective NADPH production in mitochondrial disease complex I causes inflammation and cell death.Nat Commun2020;11:2714 PMCID:PMC7264245

[11] Li Z,Allen TM.The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis.Cell Metab2006;3:321-31

[12] Zeisel SH,Caudill MA.Choline.Adv Nutr2018;9:58-60 PMCID:PMC6008955

[13] Nakatsuka A,Yamaguchi S.Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis.Sci Rep2016;6:21721 PMCID:PMC4756298

[14] Yi P,Pogribna M,Hine RJ.Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation.J Biol Chem2000;275:29318-23

[15] Bril F,Collier TS.Differences in HDL-bound apolipoproteins in patients with advanced liver fibrosis due to nonalcoholic fatty liver disease.J Clin Endocrinol Metab2022;108:42-51 PMCID:PMC9759171

[16] Homocysteine Lowering Trialists’ Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials.Am J Clin Nutr2005;82:806-12

[17] Sohouli MH,Alfardous Alazm A.A comprehensive review and meta-regression analysis of randomized controlled trials examining the impact of vitamin B12 supplementation on homocysteine levels.Nutr Rev2024;82:726-37

[18] Steenge GR,Katan MB.Betaine supplementation lowers plasma homocysteine in healthy men and women.J Nutr2003;133:1291-5

[19] Lu XT,Mo QW.Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial.Eur J Nutr2023;62:1599-610 PMCID:PMC9886420

[20] Liu C,Wang F.Effect of nutritional supplements for reducing homocysteine levels in healthy adults: a systematic review and network meta-analysis of randomized trials.Nutr Rev2025;83:e1533-43 PMCID:PMC12166197

[21] Sadre-Marandi F,Reed MC.Sex differences in hepatic one-carbon metabolism.BMC Syst Biol2018;12:89 PMCID:PMC6201565

[22] Pickett-Blakely O,Carr RM.Micronutrients in nonalcoholic fatty liver disease pathogenesis.Cell Mol Gastroenterol Hepatol2018;6:451-62 PMCID:PMC6170520

[23] Qi X,Li Y.Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography.Sci Rep2024;14:2592 PMCID:PMC10831069

[24] Yao B,Xu L.Association of serum folate with prevalence of non-alcoholic fatty liver disease among adults (NHANES 2011-2018).Front Nutr2023;10:1141156 PMCID:PMC10126427

[25] Li J,Lv Y.Association between dietary intakes of B vitamins and nonalcoholic fatty liver disease in postmenopausal women: a cross-sectional study.Front Nutr2023;10:1272321 PMCID:PMC10621796

[26] Pan J,Pang N.Dietary niacin intake and mortality among individuals with nonalcoholic fatty liver disease.JAMA Netw Open2024;7:e2354277 PMCID:PMC10835509

[27] Bril F, Lomonaco R, Orsak B, et al. Vitamin D deficiency and development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Hepatology. 2013;58:522a. Available from: https://journals.lww.com/hep/citation/2013/10001/vitamin_d_deficiency_and_development_of.657.aspx. [Last accessed on 10 Sep 2025].

[28] Abdelmalek MF,Angulo P.Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.Hepatology2009;50:1818-26

[29] Bril F,Kalavalapalli S.Role of Vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial.Diabetes Care2019;42:1481-8

[30] Kitson MT,Gordon A,Roberts SK.High-dose vitamin D supplementation and liver histology in NASH.Gut2016;65:717-8

[31] Cerletti C,Storto M.Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease.Br J Nutr2020;123:190-7